William Blair Issues Pessimistic Estimate for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at William Blair lowered their Q1 2025 earnings per share estimates for Tarsus Pharmaceuticals in a report released on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of ($0.82) for the quarter, down from their prior estimate of ($0.72). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($1.70) EPS and FY2025 earnings at ($1.70) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million.

Other research analysts have also recently issued research reports about the company. Guggenheim reiterated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays reduced their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday. The Goldman Sachs Group boosted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday. Finally, Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $44.48 on Friday. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The business’s 50-day moving average price is $50.97 and its two-hundred day moving average price is $43.13. The stock has a market cap of $1.70 billion, a PE ratio of -11.67 and a beta of 1.01.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Toronto Dominion Bank acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $105,714,000. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Tarsus Pharmaceuticals by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock valued at $3,866,000 after buying an additional 10,991 shares during the period. Finally, Woodline Partners LP lifted its stake in Tarsus Pharmaceuticals by 52.3% in the fourth quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock valued at $6,035,000 after buying an additional 37,417 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.